Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018Adjusted EBITDA for.

Total Revenues were $33.3 Million, an Increase of 24% Year-over-YearNet Income was $5.2 Million, an Increase of 6% Year-over-YearCompany Reports Continued Progress of its.

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two prominent bio-pharmaceutical companies specialized in plasma-derived protein therapeutics, today announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients. The announcement follows separate previous reports by each of the two entities in connection with initiation of development programs for such product.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2019, prior to the open of the U.S. financial markets on Wednesday, February 12, 2020. Kamada management will host an investment community conference call on Wednesday, February 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1809 406 247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13698675.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). As presented in our recent manuscript (ERJ November 2019) describing the results of Kamada’s previously completed Phase 2/3 study, AATD patients with severe lung disease treated with inhaled AAT for one year demonstrated slower FEV1 decline.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today preliminary and unaudited total revenue for the fourth quarter and full-year 2019. Total revenue for the fourth quarter of 2019 is expected to be between $31.4 million and $32.4 million.

Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were unchanged 0.00% year over year to $0.12, which beat the estimate of $0.06.Revenue of $33,290,000 rose by 24.23% year over year, which beat the estimate of $30,120,000.Outlook Kamada hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 18, 2020View more earnings on KMDATime: 08:30 AMET Webcast URL: https://www.kamada.com/events-presentations/Recent Stock Performance Company's 52-week high was at $8.00Company's 52-week low was at $4.40Price action over last quarter: Up 14.17%Company Description Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing and marketing of specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX etc. The company has Proprietary products and Distribution segments. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from Proprietary products segment and generates the majority of sales from the United States. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.See more from Benzinga * Sohu.com: Q1 Earnings Insights * Recap: Sea Q1 Earnings * Horizon Global: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV (NASDAQ: CNTG) * Forty Seven Inc (NASDAQ: FTSV)Down In The Dumps(Biotech Stocks Hitting 52-week lows on March 10) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * BioLife Solutions Inc (NASDAQ: BLFS) * bluebird bio Inc (NASDAQ: BLUE) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Celcuity Inc (NASDAQ: CELC) * Cerecor Inc (NASDAQ: CERC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enochian Biosciences Inc (NASDAQ: ENOB) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evolus Inc (NASDAQ: EOLS) * Exicure Inc (NASDAQ: XCUR) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Heron Therapeutics Inc (NASDAQ: HRTX) * Incyte Corporation (NASDAQ: INCY) * INmune Bio Inc (NASDAQ: INMB) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * TapImmune Inc. common stock (NASDAQ: MRKR) * MediciNova, Inc. (NASDAQ: MNOV) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO)ccccc * Neuronetics Inc (NASDAQ: STIM) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Radius Health Inc (NASDAQ: RDUS) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * SurModics, Inc. (NASDAQ: SRDX) * Synlogic Inc (NASDAQ: SYBX) * T2 Biosystems Inc (NASDAQ: TTOO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Unum Therapeutics Inc (NASDAQ: UMRX) * Vericel Corp (NASDAQ: VCEL) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Mallinckrodt's Global Opioid Settlement Agreement Endorsed By New York State Mallinckrodt PLC (NYSE: MNK) said the New York State Attorney General Letitia James lent support to the company's previously announced global opioid settlement, joining 47 other states and U.S. Territory Attorneys General.The State of New York and Suffolk County, together with Mallinckrodt and SpecGx LLC, have jointly filed a motion to remove the companies from the New York State opioid trial.In pre-market trading, shares were rising 13.24% to $2.48.Kamada to Work On Treatment for Severely Ill COVID-19 Patients Israeli plasma-derived biopharma Kamada Ltd. (NASDAQ: KMDA) said it plans to initiate the development of an Anti-COVID-19 polyclonal immunoglobin using is its proprietary plasma derived IgG platform technology as a potential treatment for severely ill coronavirus patients."We are working with the Israeli regulatory authorities and local medical institutions to advance our program," said Amir London, CEO of Kamada.In pre-market trading, shares were up 6.23% to $5.80.FDA Approves Bristol-Myers' Opdivo-Yervoy Combo For Liver Cancer Bristol-Myers Squibb Co's (NYSE: BMY) said the FDA approved its sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma, previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.Phio Pharma Announces Agreement to Develop Immune Enhancers Phio Pharmaceuticals Corp (NASDAQ: PHIO) has reached a new agreement with Medigene relating to its previously announced research collaboration with Helmholtz Zentrum Munchen to develop novel candidates for the use of Intasyl compounds in adoptive cell therapy to enhance immune function.The new agreement provides for Medigene contributing expertise regarding clinical development and proprietary research material. The company also has an option to an exclusive license for potential immune cell enhancers against certain fee payments.Phio shares rallied 15.30% to $3.24 in after-hours trading.NuCana's Ovarian Cancer Drug Shows Favorable Disease Control In Midstage Study NuCana PLC (NASDAQ: NCNA) announced preliminary results from part one of the Phase 2 study of single-agent Acelarin in difficult-to-treat patients with platinum-resistant ovarian cancer, which showed that out of the 45 evaluable patients, one patient achieved a complete response and two patients achieved partial responses, while 16 achieved stable disease."We are pleased with this favorable disease control rate and Acelarin's ability to achieve confirmed complete and partial responses in this very heavily pre-treated patient population," said Hugh Griffith, CEO of NuCana.Separately, the company reported fourth-quarter results showing a wider loss.View more earnings on MNKNuCana shares rose 7.25% to $7.25 in after-hours trading.Sophiris Bio Shares to Be Delisted From Nasdaq, Effective March 12 Sophiris Bio Inc (NASDAQ: SPHS), which is evaluating its topsalysin in late-stage clinical trials for urological diseases, said the Nasdaq Officer of General Counsel informed the company that the Nasdaq Hearing Panel has determined to delist its shares from the Nasdaq. Trading in the company's shares are to be suspended, effective at the open of business March 12.The company said it expects its shares to be eligible for trading on the OTC.The delisting comes in the wake of the company flouting listing standards pertaining to the minimum $2.5 million stockholder's equity requirement.The stock plummeted 39.58% to 35 cents in the after-hours trading.J&J's Lung Cancer Therapy Gets Breakthrough Designation Johnson & Johnson (NYSE: JNJ) said its Janssen unit's JNJ-61186372 has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.Roche's Biomarker-based Screening Test For Cervical Cancer Approved by FDARoche Holdings AG Basel ADR (OTC: RHHBY) said the FDA approved its CINtec PLUS Cytology, as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for HPV using the cobas 4800 HPV Test.Altimmune Soars Despite No NewsAltimmune Inc (NASDAQ: ALT) shares were sharply higher in after-hours trading, although there was no release from the company.Earnings RA Medical Systems Inc (NYSE: RMED) reported a decline in is fourth-quarter revenues from $2 million in 2018 to $1.4 million in 2019. The net loss per share narrowed from $1.18 to 72 cents. Analysts estimated a loss of $1.15 per share.The stock plunged 39.72% to 85 cents in after-hours trading.Fulgent Genetics Inc's (NASDAQ: FLGT) fourth-quarter revenues climbed 48% year-over-year to $8.4 million and the company reported non-GAAP EPS of 4 cents, in line with the consensus estimate.The stock 4.92% to $14.50 in after-hours trading.Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported fourth-quarter revenues of $2.07 million in 2019 compared to no revenues a year ago. The net loss per share narrowed from 16 cents to 5 cents, while analysts estimated a loss of 7 cents per share.The stock slipped 5.21% to 91 cents in after-hours trading.Offerings Kala Pharmaceuticals Inc (NASDAQ: KALA) said it has priced its underwritten public offering of 16 million shares at $7.89 per share, for generating gross proceeds of $126.2 million. The company expects the offering to close March 13.In premarket trading Wednesday, Kala shares were adding 11.53% to $8.80.On The Radar Earnings • Xeris Pharma (before the market open) • Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) • INmune Bio Inc (NASDAQ: INMB) (before the market open) • Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) • Calithera Biosciences Inc (NASDAQ: CALA) (after the close) • Unity Biotechnology Inc (NASDAQ: UBX) (after the close) • Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) • Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) • BioLife Solutions Inc (NASDAQ: BLFS) (after the close) • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) • Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) • Pfenex Inc (NYSE: PFNX) (after the close) • Arcturus Therapeutics Ltd (NASDAQ: ARCT) (after the close) • Novavax, Inc. (NASDAQ: NVAX) (after the close) • Global Cord Blood Corp (NYSE: CO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day

Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]

Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the Israeli Ministry of Health (IMOH). Kamada leverages its expertise and presence in the Israeli market to distribute, in Israel, more than 20 products that are manufactured by third parties.

Kamada Plans to Utilize its Hyper-Immunoglobulin (IgG) Platform Technology to Develop an Anti-Corona (COVID-19) Immunoglobulin as a Potential Therapy for Severely Ill.

At this time, I will turn the conference over to Bob Yedid with LifeSci Advisors. Good morning, this is Bob Yedid with LifeSci Advisors. Joining me from Kamada are Amir London, Chief Executive Officer; and Chaime Orlev, Chief Financial Officer.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities purchase agreement with FIMI Opportunity Funds  (FIMI), the leading private equity investor in Israel, to purchase $25 million of its ordinary shares in a private placement. No placement agent fees will be incurred by the Company in connection with the transaction.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020. Kamada management will host an investment community conference call on Monday, May 18, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13699990.

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.S. Securities and Exchange Commission (the “SEC”). The annual report, including the Company’s audited consolidated financial statements, can be accessed via the SEC’s website at https://www.sec.gov/edgar.shtml, as well as under the SEC Filings section on Kamada’s investor relations website at https://www.kamada.com/. The Company will deliver a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.

Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a U.S. Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.